Regorafenib as second-line therapy in hepatocellular carcinoma
Crossref DOI link: https://doi.org/10.1038/nrgastro.2017.7
Published Online: 2017-02-08
Published Print: 2017-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Duffy, Austin G.
Greten, Tim F.
Text and Data Mining valid from 2017-02-08
Article History
First Online: 8 February 2017
Competing interests
: The authors declare no competing financial interests.